Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ligia Craciun is active.

Publication


Featured researches published by Ligia Craciun.


Journal of Experimental Medicine | 2010

Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8α+ dendritic cells

Lionel Franz Poulin; Mariolina Salio; Emmanuel Griessinger; Fernando Anjos-Afonso; Ligia Craciun; Ji-Li Chen; Anna M. Keller; Olivier Joffre; Santiago Zelenay; Emma Nye; Alain Le Moine; Florence Faure; Vincent Donckier; David Sancho; Vincenzo Cerundolo; Dominique Bonnet; Caetano Reis e Sousa

In mouse, a subset of dendritic cells (DCs) known as CD8α+ DCs has emerged as an important player in the regulation of T cell responses and a promising target in vaccination strategies. However, translation into clinical protocols has been hampered by the failure to identify CD8α+ DCs in humans. Here, we characterize a population of human DCs that expresses DNGR-1 (CLEC9A) and high levels of BDCA3 and resembles mouse CD8α+ DCs in phenotype and function. We describe the presence of such cells in the spleens of humans and humanized mice and report on a protocol to generate them in vitro. Like mouse CD8α+ DCs, human DNGR-1+ BDCA3hi DCs express Necl2, CD207, BATF3, IRF8, and TLR3, but not CD11b, IRF4, TLR7, or (unlike CD8α+ DCs) TLR9. DNGR-1+ BDCA3hi DCs respond to poly I:C and agonists of TLR8, but not of TLR7, and produce interleukin (IL)-12 when given innate and T cell–derived signals. Notably, DNGR-1+ BDCA3+ DCs from in vitro cultures efficiently internalize material from dead cells and can cross-present exogenous antigens to CD8+ T cells upon treatment with poly I:C. The characterization of human DNGR-1+ BDCA3hi DCs and the ability to grow them in vitro opens the door for exploiting this subset in immunotherapy.


Journal of Clinical Investigation | 2010

Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans.

Pervinder Sagoo; Esperanza Perucha; Birgit Sawitzki; Stefan Tomiuk; David A. Stephens; Patrick Miqueu; Stephanie Chapman; Ligia Craciun; Ruhena Sergeant; Sophie Brouard; Flavia Rovis; Elvira Jimenez; Amany Ballow; Magali Giral; Irene Rebollo-Mesa; Alain Le Moine; Cécile Braudeau; Rachel Hilton; Bernhard Gerstmayer; Katarzyna Bourcier; Adnan Sharif; Magdalena Krajewska; Graham M. Lord; Ian S.D. Roberts; Michel Goldman; Kathryn J. Wood; Kenneth A. Newell; Vicki Seyfert-Margolis; Anthony N. Warrens; Uwe Janssen

Identifying transplant recipients in whom immunological tolerance is established or is developing would allow an individually tailored approach to their posttransplantation management. In this study, we aimed to develop reliable and reproducible in vitro assays capable of detecting tolerance in renal transplant recipients. Several biomarkers and bioassays were screened on a training set that included 11 operationally tolerant renal transplant recipients, recipient groups following different immunosuppressive regimes, recipients undergoing chronic rejection, and healthy controls. Highly predictive assays were repeated on an independent test set that included 24 tolerant renal transplant recipients. Tolerant patients displayed an expansion of peripheral blood B and NK lymphocytes, fewer activated CD4+ T cells, a lack of donor-specific antibodies, donor-specific hyporesponsiveness of CD4+ T cells, and a high ratio of forkhead box P3 to alpha-1,2-mannosidase gene expression. Microarray analysis further revealed in tolerant recipients a bias toward differential expression of B cell-related genes and their associated molecular pathways. By combining these indices of tolerance as a cross-platform biomarker signature, we were able to identify tolerant recipients in both the training set and the test set. This study provides an immunological profile of the tolerant state that, with further validation, should inform and shape drug-weaning protocols in renal transplant recipients.


Journal of Immunological Methods | 2002

Cytokine mRNA quantification by real-time PCR

Patrick Stordeur; Lionel Poulin; Ligia Craciun; Ling Zhou; Liliane Schandené; Aurore de Lavareille; Stanislas Goriely; Michel Goldman

Real-time PCR represents a new methodology that accurately quantifies nucleic acids. This has been made possible by the use of fluorogenic probes, which are presented in two forms, namely hydrolysis probes (also called TaqMan probes) and hybridisation probes. We decided to apply this methodology to cytokine mRNA quantification and this led us to the development of a protocol that provides an easy way to develop and perform rapidly real-time PCR on a Lightcycler instrument. It was made possible by the use of freely available software that permits a choice of both the hydrolysis probe and the primers. We firstly demonstrated that the reproducibility of the method using hydrolysis probes compares favourably with that obtained with hybridisation probes. We then applied this technique to determine the kinetics of IL-1ra, IL-1beta, IL-5, IL-13, TNF-alpha and IFN-gamma induction upon stimulation of human peripheral blood mononuclear cells (PBMC) by phytohaemagglutinin (PHA). Finally, the method was also used successfully to demonstrate that IFN-alpha induces IL-10 mRNA accumulation in human monocytes.


Liver Transplantation | 2006

Early immunosuppression withdrawal after living donor liver transplantation and donor stem cell infusion

Vincent Donckier; Roberto Troisi; Alain Le Moine; Michel Toungouz; S Ricciardi; Isabelle Colle; Hans Van Vlierberghe; Ligia Craciun; Myriam Libin; Marleen Praet; Lucien Noens; Patrick Stordeur; Marc Andrien; Micheline Lambermont; Michel Gelin; Nadine Bourgeois; Michael Adler; Bernard de Hemptinne; Michel Goldman

Long‐term results of organ transplantation are still limited by serious side effects of immunosuppressive drugs. A major issue, therefore, is to elaborate novel therapeutic protocols allowing withdrawal or minimization of immunosuppressive therapy after transplantation. We report on 3 patients prospectively enrolled in an original protocol designed to promote graft acceptance in living donor liver transplantation, using posttransplant conditioning with high doses of antithymocyte globulin followed by injection of donor‐derived stem cells. In 2 patients, early immunosuppression withdrawal was possible, without subsequent graft deterioration. In these 2 cases, in vitro studies showed indices of immunological tolerance as assessed by specific hyporesponsiveness to donor alloantigens in mixed lymphocytes culture. In the third patient, acute rejection rapidly occurred after discontinuation of immunosuppression, and minimal immunosuppression has to be maintained during long‐term follow‐up. In this case, a clearly distinct immunoreactive profile was observed as compared to tolerant patients, as no specific modulation of the antidonor response was observed in vitro. Of note, no macrochimerism could be detected in any of the 3 patients during the follow‐up. In conclusion, these clinical observations demonstrated that, despite the absence of macrochimerism, donor stem cells infusion combined with recipient conditioning may allow early immunosuppression withdrawal or minimization after liver transplantation. Liver Transpt 12:1523–1528, 2006.


Transplantation | 2002

Increased production of interleukin-10 and interleukin-1 receptor antagonist after extracorporeal photochemotherapy in chronic graft-versus-host disease

Ligia Craciun; Patrick Stordeur; Liliane Schandené; Hugues Duvillier; Dominique Bron; Micheline Lambermont; Michel Goldman

Background. Mechanisms of action of extracorporeal photochemotherapy (ECP) in graft-versus-host disease are incompletely understood. It has been proposed that phagocytosis of apoptotic bodies by monocytes and macrophages induces their activation, a process that increases production of immunosuppressive cytokines. We analyzed apoptosis and cytokine secretion in an autologous coculture system combining peripheral blood lymphocytes (PBL) obtained after ex vivo ECP treatment and nonirradiated peripheral blood mononuclear cells (PBMC). Methods. We studied 11 leukapheresis products treated by ECP from six patients with resistant limited or extensive chronic graft-versus-host disease. Purified PBL obtained by monocyte depletion of the buffy coat from leukapheresis products were mixed with nonirradiated PBMC. Nonirradiated PBL were used as control. Cytokine production was tested at the mRNA level by real-time reverse transcriptase-polymerase chain reaction for interleukin (IL)-10, IL-1 receptor antagonist (IL-1Ra), IL-1&bgr;, tumor necrosis factor-&agr;, and IL-12p40. Results. Morphologic analysis and flow cytometry displayed important lymphocyte apoptotic features culminating at 24 to 48 hr. Coculture of patient’s PBMC with ultraviolet-irradiated PBL as compared with nonirradiated PBL resulted in significant increase of IL-10 mRNA (3418±1015 versus 10596±3402 mRNA copy numbers;P =0.001) and IL-1Ra mRNA (23890±6166 versus 41767±10181 mRNA copy numbers;P =0.001). Incubation with a neutralizing anti-IL-10 monoclonal antibody resulted in a marked decrease of IL-1Ra mRNA levels. Conclusion. Our findings are consistent with the fact that ECP modifies patient’s autologous lymphocytes by inducing a process of apoptosis that activates monocytes and macrophages, leading to increased synthesis of IL-10 and IL-1Ra mRNAs. The induction of this latter mediator is dependent on IL-10.


Transplantation | 2013

Expansion of memory-type CD8⁺ T cells correlates with the failure of early immunosuppression withdrawal after cadaver liver transplantation using high-dose ATG induction and rapamycin

Vincent Donckier; Ligia Craciun; Patrick Miqueu; Roberto Troisi; Valerio Lucidi; Xavier Rogiers; Nathalie Boon; Delphine Degré; Alexis Buggenhout; Christophe Moreno; Thierry Gustot; Maurizio Sainz-Barriga; Nadine Bourgeois; Isabelle Colle; Hans Van Vlierberghe; Mohammed Amrani; Myriam Remmelink; Arnaud Lemmers; Dave L. Roelen; Frans H.J. Claas; Petra Reinke; Birgit Sawitzki; H.-D. Volk; Alain Le Moine; Bernard de Hemptinne; Michel Goldman

Background We report on a pilot study investigating the feasibility of early immunosuppression withdrawal after liver transplantation (LT) using antithymocyte globulin (ATG) induction and rapamycin. Methods LT recipients received 3.75 mg/kg per day ATG from days 0 to 5 followed by rapamycin-based immunosuppression. In the absence of acute rejection (AR), rapamycin was withdrawn after month 4. Immunomonitoring included analysis of peripheral T-cell phenotypes and clonality, cytokine production in mixed lymphocyte reaction, and characterization of intragraft infiltrating cells. Results Ten patients were enrolled between October 2009 and July 2010. In the first three patients, complete withdrawal of immunosuppression after month 4 led to AR. No further withdrawals of immunosuppressive were attempted. Two AR occurred in the remaining seven patients. ATG induced profound T-cell depletion followed by CD8+ T-cell reexpansion exhibiting memory/effector-like phenotype associated with progressive oligoclonal T-cell expansion (V&bgr;/HPRT ratio) and gradually enhanced anti-cytomegalovirus and anti–Epstein-Barr virus T-cell frequencies. Patients developing AR were characterized by decreased TCAIM expression. AR were associated with increased donor-specific production of interferon (IFN)-&ggr; and interleukin (IL)-17, increased intragraft expression of IFN-&ggr; mRNA, and significant CD8+ T-cell infiltrates colocalizing with IL-17+ cells. Conclusion High-dose ATG followed by short-term rapamycin treatment failed to promote early operational tolerance to LT. AR correlates with expansion of memory-type CD8+ T cells and increased levels of IFN-&ggr; and IL-17 in mixed lymphocyte reaction and in the graft. This suggests that resistance and preferential expansion of effector memory T-cell in lymphopenic environment could represent the major barrier for establishment of tolerance to LT in approaches using T-cell–depleting induction.


Transplantation | 2008

IL-17 production elicited by allo-major histocompatibility complex class II recognition depends on CD25posCD4pos T cells.

Fleur Samantha Benghiat; Ligia Craciun; Virginie De Wilde; Tiffany Dernies; Carole Kubjak; Frédéric Lhommé; Michel Goldman; Alain Le Moine

Background. Interleukin (IL)-17 is involved in autoimmune inflammatory disorders and naturally occurring CD25pos regulatory T cells were shown to promote IL-17 synthesis. Because IL-17 is overproduced in certain types of allograft rejection, it is important to characterize the cells responsible for IL-17 synthesis and to define how IL-17 is regulated during alloimmune responses. Methods. Splenic CD4pos T cells were isolated from C57BL/6 mice and fractionated according to CD25 expression. T cells were stimulated by major histocompatibility complex class II-mismatched bone marrow-derived dendritic cells from bm12 mice, either immature or made mature by exposure to lipopolysaccharide. To track T cell populations, CD25negCD4pos and CD25posCD4pos were isolated from Thy1.1 and congenic Thy1.2 mice, respectively. Cell proliferation was quantified by CFSE dilution. IL-17-producing cells and FOXP3pos cells were enumerated by intracytoplasmic staining and cytokine levels in culture supernatants were measured by ELISA. Results. Addition of CD25posCD4pos T cells to CD25negCD4pos T cells inhibited IL-2, interferon-γ, and IL-13 production but promoted IL-17 synthesis on stimulation by allogenic immature DC. In this setting, IL-17 originated from CD25intCD4posFOXP3neg memory T cells, which depend on IL-2 to produce IL-17. Alloreactive CD25negCD4pos T cells were also induced to produce IL-17 when stimulated by mature DC in the presence of CD25highCD4posFOXP3pos T cells. Conclusions. We conclude that (1) the cellular source of IL-17 during an antiallo major histocompatibility complex class II response depends on the maturation status of allogenic DC, (2) whereas suppressing Th1 and Th2 cytokine synthesis, naturally occurring regulatory T cells, allow IL-17 production by alloreactive CD4pos T cells.


Transplantation | 2009

Acute Liver Transplant Rejection Upon Immunosuppression Withdrawal in a Tolerance Induction Trial: Potential Role of IFN-gamma-secreting CD8(+) T Cells

Vincent Donckier; Ligia Craciun; Valerio Lucidi; Alexis Buggenhout; Roberto Troisi; Xavier Rogiers; Nathalie Boon; Thierry Gustot; Christophe Moreno; Nadine Bourgeois; Isabelle Colle; Hans Van Vlierberghe; Nathalie Nagy; Marleen Praet; Tiffany Dernies; Mohammed Amrani; Patrick Stordeur; Bernard de Hemptinne; Michel Goldman

We designed a pilot trial in cadaveric liver transplantation to determine whether induction with antithymocyte globulins (ATG) and sirolimus would allow immunosuppression withdrawal. Patients received ATG 3.75 mg/kg per day from day 1 to 5 after transplantation followed by sirolimus for 4 to 6 months. We monitored interleukin (IL)-7 serum levels, interferon (IFN)-γ, and IL-2 mRNA accumulation in mixed leukocyte reaction and intragraft IFN-γ mRNA expression. In the first three patients, immunosuppression discontinuation was followed by reversible acute rejection occurring on days 280, 246, and 163 posttransplantation, corresponding to days 140, 40, and 39 after drug withdrawal, respectively. At the time of rejection, blood CD8+ T-cells counts had returned to or above pretransplant levels in two of three patients, whereas CD4+ T-cell count remained low. IL-7 serum levels rose in all three patients in the first months after transplantation and IFN-γ mRNA accumulated in mixed leukocyte reaction between recipient T cells and donor spleen cells at the time of rejection. High levels of IFN-γ mRNA were consistently detected in liver biopsy performed at the time of rejection. In conclusion, lymphopenia-induced IL-7 production after induction with ATG and sirolimus might lead to emergence of IFN-γ-secreting CD8+ T-cells responsible for acute rejection after immunosuppression withdrawal.


Embo Molecular Medicine | 2017

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib

Eric Raspé; Katia Coulonval; Jaime Miguel Pita; Sabine Paternot; Françoise Rothé; Laure Twyffels; Sylvain Brohée; Ligia Craciun; Denis Larsimont; Véronique Kruys; Flavienne Sandras; Isabelle Salmon; Steven Van Laere; Martine Piccart; Michail Ignatiadis; Christos Sotiriou; Pierre P. Roger

Cyclin D‐CDK4/6 are the first CDK complexes to be activated in the G1 phase in response to oncogenic pathways. The specific CDK4/6 inhibitor PD0332991 (palbociclib) was recently approved by the FDA and EMA for treatment of advanced ER‐positive breast tumors. Unfortunately, no reliable predictive tools are available for identifying potentially responsive or insensitive tumors. We had shown that the activating T172 phosphorylation of CDK4 is the central rate‐limiting event that initiates the cell cycle decision and signals the presence of active CDK4. Here, we report that the profile of post‐translational modification including T172 phosphorylation of CDK4 differs among breast tumors and associates with their subtypes and risk. A gene expression signature faithfully predicted CDK4 modification profiles in tumors and cell lines. Moreover, in breast cancer cell lines, the CDK4 T172 phosphorylation best correlated with sensitivity to PD0332991. This gene expression signature identifies tumors that are unlikely to respond to CDK4/6 inhibitors and could help to select a subset of patients with HER2‐positive and basal‐like tumors for clinical studies on this class of drugs.


Transplantation Proceedings | 2009

Induction of tolerance in solid organ transplantation: the rationale to develop clinical protocols in liver transplantation.

Vincent Donckier; A. Sanchez-Fueyo; Ligia Craciun; Valerio Lucidi; Alexis Buggenhout; Roberto Troisi; Xavier Rogiers; Nadine Bourgeois; Nathalie Boon; Christophe Moreno; Isabelle Colle; H. Van Vlierberghe; B. de Hemptinne; Michel Goldman

Minimization or withdrawal of immunosuppressive treatments after organ transplantation represents a major objective for improving quality of life and long-term survival of grafted patients. Such a goal may be reached under some clinical conditions, particularly in liver transplantation, making these patients good candidates for tolerance trials. In this context in liver transplantation, the central questions are (1) how to promote the natural propensity of the liver graft to be accepted, (2) which type of immunosuppressive drug should be used for induction and maintenance, and (3) which biomarkers could be used to discriminate tolerant patients from those requiring long-term immunosuppression. Induction therapies using aggressive T-cell-depleting agents may favor graft acceptance. However, persistent and/or rapidly reemerging cell lines, such as memory-type cells or CD8(+) T cells, could represent a significant barrier for induction of tolerance. The type of maintenance drugs also remains questionable. Calcineurin inhibitors may be eventually deleterious in the context of tolerance protocols, through inhibitory effects on regulatory T cells, that are not observed with rapamycin. In conclusion, significant efforts must be made to achieve reliable strategies for immunosuppression minimization or withdrawal after organ transplantation into the clinics.

Collaboration


Dive into the Ligia Craciun's collaboration.

Top Co-Authors

Avatar

Michel Goldman

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar

Isabelle Colle

Ghent University Hospital

View shared research outputs
Top Co-Authors

Avatar

Patrick Stordeur

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar

Roberto Troisi

Ghent University Hospital

View shared research outputs
Top Co-Authors

Avatar

Vincent Donckier

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar

Nadine Bourgeois

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar

Alexis Buggenhout

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Denis Larsimont

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge